Fred Hutch Cancer Center | Strategic Alliance Partners

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Rahul Banerjee, MD FACP, discusses the FDA’s decision to add a class-wide boxed warning for secondary malignancies on all approved CAR T-cell therapies.

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.

Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.

Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.